Interrogation of human hematopoiesis at single-cell and single-variant resolution. by Ulirsch, Jacob C et al.
UC San Diego
UC San Diego Previously Published Works
Title
Interrogation of human hematopoiesis at single-cell and single-variant resolution.
Permalink
https://escholarship.org/uc/item/30z8m9tw
Journal
Nature genetics, 51(4)
ISSN
1061-4036
Authors
Ulirsch, Jacob C
Lareau, Caleb A
Bao, Erik L
et al.
Publication Date
2019-04-01
DOI
10.1038/s41588-019-0362-6
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Interrogation of human hematopoiesis at single-cell and single-
variant resolution
Jacob C. Ulirsch1,2,3,4,*, Caleb A. Lareau1,2,3,4,5,*, Erik L. Bao1,2,3,6,*, Leif S. Ludwig1,2,3, 
Michael H. Guo3,7,8,9, Christian Benner10,11, Ansuman T. Satpathy12, Vinay K. Kartha3, 
Rany M. Salem3,7,8,9, Joel N. Hirschhorn3,7,8,9, Hilary K. Finucane3,13, Martin J. Aryee3,5,14, 
Jason D. Buenrostro3,15,+, and Vijay G. Sankaran1,2,3,16,+
1.Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, 
MA, USA. 2.Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical 
School, Boston, MA, USA. 3.Broad Institute of MIT and Harvard, Cambridge, MA, USA. 4.Program 
in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA, USA. 5.Department 
of Pathology, Massachusetts General Hospital, Boston, MA, USA. 6.Harvard-MIT Health Sciences 
and Technology, Harvard Medical School, Boston, MA, USA. 7.Division of Endocrinology, Boston 
Children’s Hospital, Harvard Medical School, Boston, MA, USA. 8.Department of Genetics, 
Harvard Medical School, Boston, MA, USA. 9.Center for Basic and Translational Obesity 
Research, Boston Children’s Hospital, Boston, MA, USA. 10.Institute for Molecular Medicine 
Finland, University of Helsinki, Helsinki, Finland. 11.Department of Public Health, University of 
Helsinki, Helsinki, Finland. 12.Department of Pathology, Stanford University School of Medicine, 
Stanford, CA, USA. 13.Schmidt Fellows Program, Broad Institute of MIT and Harvard, Cambridge, 
MA, USA. 14.Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, 
USA. 15.Harvard Society of Fellows, Harvard University, Cambridge, MA, USA. 16.Harvard Stem 
Cell Institute, Cambridge, MA, USA.
Abstract
Widespread linkage disequilibrium and incomplete annotation of cell-to-cell state variation 
represent substantial challenges to elucidating mechanisms of trait-associated genetic variation. 
Here, we perform genetic fine-mapping for blood cell traits in the UK Biobank to identify putative 
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causal variants. These variants are enriched in genes encoding for proteins in trait-relevant 
biological pathways and in accessible chromatin of hematopoietic progenitors. For regulatory 
variants, we explore patterns of developmental enhancer activity, predict molecular mechanisms, 
and identify likely target genes. In several instances, we localize multiple independent variants to 
the same regulatory element or gene. We further observe that variants with pleiotropic effects 
preferentially act in common progenitor populations to direct the production of distinct lineages. 
Finally, we leverage fine-mapped variants in conjunction with continuous epigenomic annotations 
to identify trait-cell type enrichments within closely related populations and in single cells. Our 
study provides a comprehensive framework for single-variant and single-cell analyses of genetic 
associations.
Editorial summary:
Fine mapping of blood cell traits in UK Biobank identifies putative causal variants and enrichment 
of fine-mapped variants in accessible chromatin of hematopoietic progenitor cells. The study 
provides an analytical framework for single-variant and single-cell analyses of genetic 
associations.
Hematopoiesis is a paradigm of cellular differentiation that is highly coordinated to ensure 
balanced proportions of mature blood cells1. Despite our sophisticated understanding gained 
primarily from model organisms, many aspects of this process remain poorly understood in 
humans. At the population level, there is substantial variation in commonly measured blood 
cell traits, such as hemoglobin levels and specific blood cell counts, which can manifest as 
diseases at extreme ends of the spectrum2. Identifying genetic variants that drive these 
differences in blood cell traits in human populations may reveal regulatory mechanisms and 
genes critical for blood cell production and hematologic diseases.
To these ends, genome-wide association studies (GWAS) have identified thousands of 
genomic loci linked to complex phenotypes including blood cell traits3, but a major 
challenge has been the identification of causal genetic variants and relevant cell types 
underlying the observed associations4. In particular, linkage disequilibrium (LD) has 
confounded the precise identification of functional variants. In an effort to address these 
issues, several analytical approaches have been developed. The first, termed genetic fine-
mapping, attempts to resolve trait-associated loci to likely causal variants by modeling LD 
structure and the strength of associations. In practice, a major limitation has been the 
computational burden imposed when allowing for multiple causal variants, and thus methods 
that assume exactly one causal variant per locus are most commonly used5,6, despite strong 
evidence that many loci contain multiple independent associations7–10.
The second suite of approaches focus instead on identifying functional tissue enrichments. It 
has been well established that ~80–90% of associated loci do not tag coding variants and 
that ~40–80% of the narrow-sense heritability of many complex traits can be resolved to 
genomic regulatory regions11,12. Given this observation, tissue-specific measurements of 
regulatory element activity are often overlapped with significant loci (e.g. epigenomic fine-
mapping) or with polygenic signal from millions of variants (e.g. partitioned heritability) in 
order to identify variants and cell types most likely to underlie the measured trait or 
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disease11,13. These enrichment methods have revealed causal tissues for diseases, such as 
pancreatic islets in diabetes13 and central nervous system cells in schizophrenia11, but are 
only beginning to be applied to highly related traits and cell types within single systems, 
such as the hematopoietic hierarchy.
To gain insights into hematopoietic lineage commitment and differentiation, we performed 
GWASs and genetic fine-mapping for 16 blood cell traits on individuals from the UK 
Biobank3, identifying multiple likely causal variants in hundreds of individual regions. We 
comprehensively annotated fine-mapped variants and identified high confidence molecular 
mechanisms and putative target genes at scale. This allowed us to not only gain insights into 
patterns of developmental regulation, but to learn about the pleiotropic regulatory processes 
underlying blood cell production and maintenance. Finally, we describe and validate a novel 
method (g-chromVAR) to discriminate between closely related cell types in an effort to 
identify relevant stages of hematopoiesis that are affected by these common genetic variants. 
Applying g-chromVAR to single hematopoietic cell data revealed substantial heterogeneity 
of genetic enrichment within classically defined hematopoietic progenitor populations. Thus, 
we demonstrate that using a well-powered method to identify cell populations that are trait-
relevant provides a critical step towards broadly deciphering causal mechanisms underlying 
phenotypic variation.
Results
Fine-mapping pinpoints hundreds of likely causal variants.
We performed GWASs on ~115,000 individuals from the UK Biobank (UKB) for 16 blood 
cell traits representing 7 distinct hematopoietic lineages (erythroid, platelet, lymphocyte, 
monocyte, and granulocyte (neutrophil, eosinophil, and basophil)) (Fig. 1a). Similar to 
previous reports, these traits were highly heritable, with common genetic variants explaining 
an average of 15.4% of narrow-sense heritability (hg2)14 (Supplementary Fig. 1). Traits from 
the same lineage, such as red blood cell (RBC) count and hemoglobin (rg = 0.89, P = 7.1 × 
10−25), typically had high genetic correlations, whereas traits from distinct lineages had low 
genetic correlations with some exceptions, such as platelet count and lymphocyte count (rg = 
0.26, P = 3.8 × 10−18) (Supplementary Fig. 1). This suggests that the genetic regulation of 
blood production could potentially occur across various stages of hematopoiesis.
To begin to dissect the nature and stage-specificity of these genetic effects, we performed 
genetic fine mapping to identify high confidence variants across 2,056 3-Mb regions 
containing a genome-wide significant association. Traditional fine-mapping approaches 
assume only one causal variant per locus and are either agnostic to LD or use small 
reference panels, which are inaccurate when scaled to large sample sizes15. To overcome 
these limitations, we calculated LD directly from the imputed genotype probabilities 
(dosages) for individuals in our GWASs, rather than from a hard-called reference panel (Fig. 
1b).
Across all common variants (MAF > 0.1%, INFO16 > 0.6) in 2,056 regions, our method 
identified 38,654 variants with > 1% posterior probability (PP) of being causal for a trait 
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association, comprising a significant proportion of narrow-sense heritability explained by all 
common variants (trait average of 24.9% of total hg2 for PP > 0.01) (Supplementary Fig. 1 
and Supplementary Table 1). 993 regions (48%) contained at least one variant with PP > 
0.50 (Fig. 1c), providing strong evidence that our approach was successful in pinpointing 
causal variants. The posterior expected number of independent causal variants was > 2 for 
35% of regions and > 3 for 13% of regions (Fig. 1d). Given their increased complexity, 
regions with a greater expected number of causal variants had lower top configuration PPs 
(Supplementary Fig. 2 and Supplementary Table 2). The majority of variants (74%) with PP 
> 0.75 had MAF > 5% (Fig. 1e), consistent with the known polygenic nature of blood cell 
traits3. Fine-mapped variants had potentially diverse mechanisms, ranging from putative 
regulatory variants in accessible chromatin (AC) to coding variants, including 164 unique 
missense variants and 6 loss of function variants with PP > 0.10 (Fig. 1f, Supplementary Fig. 
3 and Supplementary Table 3).
To validate our approach, we investigated the overlap of fine-mapped variants (binned by 
PP) with several annotations previously shown to be enriched for GWAS signals (Fig. 
1g)11,12. To generate a null distribution, we locally shifted annotations within a 3-Mb 
window, similar to the method implemented in GoShifter17. We observed minimal 
enrichment for intronic and untranslated regions of genes, but found strong, focal, and 
stepwise enrichments across higher PP bins for hematopoietic AC, promoters, and coding 
regions (OR = 4.2, 2.9, and 8.5 for PP > 0.75, respectively) (Fig. 1f)11,12,17. Notably, strong 
enrichments persisted even after we excluded all variants with high correlation (R2 > 0.8) to 
the sentinel variants at each locus (Supplementary Fig. 3).
Dissecting mechanisms of core gene regulation in hematopoiesis.
We next sought to delineate the precise mechanisms underlying how fine-mapped genetic 
variants affect hematopoietic traits. For all 140,739 variants with PP > 0.001 we combined 
several lines of functional and predictive evidence to better understand the (i) cell 
populations, (ii) molecular mechanisms, and (iii) target genes involved in blood cell 
production (Supplementary Fig. 4). First, we identified fine-mapped (PP > 0.10) non-
synonymous and loss of function coding variants in 77 RBC, 59 platelet, 20 monocyte, 28 
lymphocyte, and 46 granulocyte (neutrophil, basophil, and eosinophil) trait genes 
(Supplementary Table 3). Within the set of genes identified from RBC trait variants, we 
identified both validated GWAS genes (SH2B318, TRIM5819) (Supplementary Fig. 5) and 
several Mendelian disease genes for diverse RBC disorders (HFE, TMPRSS6, PFKM, 
PKLR, PIEZO1, SPTA1, ANK1, RHD, GYPA, KLF1)20. Genes perturbed by fine-mapped 
coding variants were enriched for trait-relevant known and novel biological pathways. For 
example, RBC trait genes were involved in iron homeostasis, platelet trait genes in 
coagulation and wound healing, lymphocyte trait genes in T cell migration and activation, 
and monocyte and granulocyte trait genes in cytokine and inflammatory responses 
(Supplementary Fig. 6 and Supplementary Table 3). Of note, we identified several pathways 
corresponding to cholesterol and lipid regulation that were enriched in RBC trait genes 
(Supplementary Fig. 6), suggesting a connection between lipid metabolism and RBCs, 
which are major stores of cholesterol21.
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To investigate the exact stages of hematopoietic differentiation during which variants could 
regulate transcription, we overlapped fine-mapped variants (PP > 0.10) with chromatin 
accessibility profiles (ATAC-seq) of 18 hematopoietic progenitor, precursor, and 
differentiated cell populations primarily sorted from the bone marrow or blood of healthy 
donors (Fig. 1a, Supplementary Fig. 7 and Supplementary Table 4). Across traits 
representing the five major blood cell lineages, we used k-means clustering to categorize the 
developmental timing of AC peaks containing fine-mapped variants (Fig. 2A–B, 
Supplementary Fig. 8). For example, across RBC traits, we identified 80 fine-mapped 
regulatory variants, of which 26% (21/80) were restricted to erythroid progenitors, 18% 
(14/80) were restricted to megakaryocyte-erythroid progenitors (MEPs) and erythroid 
progenitors, and 29% (23/80) could regulate transcription across the entire erythroid lineage 
from hematopoietic stem cells (HSCs) to erythroid progenitors, whereas 14% (11/80) could 
only act in other hematopoietic lineages (Fig. 2a). In some cases, we identified small clusters 
of variants that followed slightly different regulatory programs, such as variants that could 
only regulate transcription in upstream multipotent progenitors and lymphocyte variants that 
could regulate transcription in T cell, but not B cell, subsets (Fig. 2a,b and Supplementary 
Fig. 8).
Next, we investigated the molecular mechanisms underlying fine-mapped regulatory 
variants. To nominate a high confidence molecular mechanism, we required that a variant (i) 
disrupt one of 426 motifs corresponding to known binding preferences of human TFs22 and 
(ii) show occupancy by that specific TF in a relevant hematopoietic primary tissue or cell 
line, based on 2,115 uniformly processed ChIP-seq profiles23. In total, we identified one or 
more such mechanisms for 145 distinct fine-mapped non-coding variants (Fig. 2c). 
Specifically, we identified 13 RBC, 28 platelet, 8 monocyte, 11 lymphocyte, and 18 
granulocyte high confidence molecular mechanisms for variants also in primary 
hematopoietic AC (Fig. 2a,b, Supplementary Fig. 8 and Supplementary Table 5). These 
variants most commonly disrupted the binding sites of key transcriptional regulators of 
hematopoietic lineage commitment and differentiation (FDR < 10% for 33 TFs). For 
example, we observed 7 PU.1 (SPI1)24,25, 6 ERG26–28, 4 FLI128,29, 3 IRF430, and 3 
RUNX131,32 binding site disrupting variants associated with platelet traits (Fig. 2c,d), in 
addition to many other compelling lineage-specific regulatory mechanisms for experimental 
follow-up (Supplementary Fig. 8 and Supplementary Note).
Finally, in order to identify high confidence target genes of fine-mapped regulatory variants, 
we built hematopoietic-specific enhancer-promoter maps using (i) measurements of physical 
DNA interactions in 15 primary hematopoietic cell populations from promoter capture Hi-C 
(PCHi-C)33 and (ii) the correlation between chromatin accessibility and cis gene expression 
across 16 primary hematopoietic populations34,35. Altogether, we identified one or more 
experimentally supported target genes for 415 variant-trait associations, providing testable 
biological hypotheses for 79% of fine-mapped regulatory variants (Fig. 2a,b, Supplementary 
Figs. 5 and 8, and Supplementary Tables 6 and 7). Interestingly, a number of variants were 
predicted to disrupt the transcription of hematopoietic TFs (Fig. 2d,e and Supplementary 
Fig. 8). For example, IRF8 and CEBPA, two essential TFs involved in monocyte 
differentiation36,37, are targets of fine-mapped monocyte count associated variants that fall 
within monocyte precursor AC (Fig. 2e). Similarly, we determined that GFI1B, KLF2, and 
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MEF2C are targets of fine-mapped variants in progenitor-specific AC for mean reticulocyte 
volume, lymphocyte count, and platelet count, respectively (Fig. 2e). Overall, this functional 
analysis will likely facilitate experimental investigation into how common genetic variants 
regulate hematopoietic lineage commitment and differentiation.
Regions with multiple causal variants.
We next conducted a closer examination of the 785 trait-associated regions with multiple 
independent causal signals. Amongst proximal pairs of variants in which both variants had 
PP > 0.50, the majority were > 10 kb apart (76%), although 7 pairs were within fewer than 
100 bp (Supplementary Fig. 9 and Supplementary Table 8). Across all pairs, 42% of the 
variants were of the same class (e.g. coding-coding), and pairs of variants in AC but in 
different regulatory regions within 1 Mb were typically lineage-specific (Supplementary Fig. 
9). Examples of coding-coding pairs include hemoglobin-associated rs1800730 and 
rs1799945 (PP > 0.66; 4 bp apart) in HFE, the classic gene mutated in hereditary 
hemochromatosis, WBC count-associated rs146125856 and rs148783236 (PP > 0.98; 24 bp 
apart) in USP8, which encodes an immune-specific ubiquitin ligase and is mutated in 
Cushing’s disease38,39, and MPV-associated rs41303899 and rs415064 (PP > 0.76; 835 bp 
apart) in TUBB1, which encodes a β-tubulin protein important for pro-platelet formation 
that is mutated in monogenic forms of macrothrombocytopenia40.
Although there were several other interesting pairs of variants in AC (see Supplementary 
Note and Supplementary Fig. 10), we specifically investigated the RBC count association at 
the CCND3 locus, in which we previously identified a causal variant and its target gene41. 
At this locus, our current approach correctly identified the known causal variant (rs9349205) 
as the primary association, as well as ~4 additional independent signals, including a 
secondary imputed variant (rs112233623) associated with decreased RBC count (Fig. 3a–c). 
Stepwise conditional analysis further validated these findings (Fig. 3b). Notably, these 
variants were missed by fine-mapping if we instead used LD estimated from either the 
UK10K whole genome sequencing (WGS) reference panel or hard-called variants from the 
UKB population (Supplementary Fig. 11), highlighting the importance of calculating LD 
using imputed genotype dosages from the GWAS population. Remarkably, rs112233623 is 
only 161 bp from rs9349205, and both lie within erythroid-specific AC (Fig. 3d). Luciferase 
reporter assays showed that each variant affected enhancer activity independently with minor 
allele effects in opposing directions, consistent with the genetic directionality (Fig. 3e). At a 
separate locus associated with platelet traits, we similarly observed a large number of 
independent signals (~8), allowing us to identify a variant pair (rs49950 and rs12005199; PP 
> 0.99; 123 bp apart) within a single AC region ~20 kb upstream of AK3, a gene whose 
zebrafish homolog is essential for platelet (thrombocyte) formation (Fig. 3f–i)42. 
Importantly, we again observed that each variant significantly affected enhancer activity 
additively and in concordance with population phenotypes (Fig. 3j).
Mechanisms of pleiotropic variants across distinct blood cell lineages.
We next sought to examine the effects of variants associated with two or more of the seven 
distinct blood cell types for which phenotypes were available in the UK Biobank. We 
hypothesized that these pleiotropic variants could either (i) tune overall blood production by 
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simultaneously increasing or decreasing the levels of terminal blood cells across multiple 
lineages or (ii) switch blood cell production such that one lineage is favored at the expense 
of others (Fig. 4a).
We restricted our analyses to quantified blood cell counts for interpretability and identified 
172 pleiotropic variants that co-localized43 (PP > 0.10) across two or more traits (Fig. 4b–d, 
Supplementary Fig. 12, and Supplementary Table 9). Surprisingly, 91% (156/172) of these 
variants exhibited a tuning mechanism, modifying two or more lineages in the same 
direction, whereas the remaining 9% (16/172) favored one lineage at the expense of other 
lineages (P = 5.08 × 10−30; Binomial test). Regardless of direction, 88% of all pleiotropic 
variants were non-coding, and those in regions of AC had 60% more ATAC-seq reads in 
progenitors than terminal cell types (mean 4.01 vs. 2.44 counts per million; P = 0.025; 
Student’s t-test), consistent with the hypothesis that many of these variants act in common 
progenitor cell populations44,45.
One example of a variant exhibiting a switch mechanism is rs78744187 (PP = 0.99 and 
0.99), which increases RBC count, while concomitantly decreasing basophil count (Fig. 4c). 
rs78744187 is located in an enhancer specific for CMPs, which encompasses a 
heterogeneous population containing progenitors for both basophils and RBCs, 
approximately 36 kb downstream of CEBPA, which encodes for a key myeloid TF46. We 
previously reported the association between rs78744187 and basophil count, but not RBC 
count, and showed that this variant switches the production of the closely related basophil 
and mast cell lineages45. A second switch variant, rs218265 (PP = 0.99 and 0.64), located 
within a gene desert 1.15 Mb upstream of KIT, increases neutrophil count but decreases 
RBC count. KIT encodes the receptor protein for stem cell factor, a growth stimulating 
cytokine involved in hematopoietic progenitor cell proliferation47. rs218265 falls within a 
region of AC that is exclusively open in multipotential and heterogenous populations (Fig. 
4d), consistent with a role for this enhancer variant in regulating KIT expression in common 
upstream progenitors of neutrophils and RBCs. Taken together, our results suggest that 
tuning the dosage of key regulatory genes in upstream progenitors may switch the 
production of one lineage in favor of another during the early stages of lineage commitment.
As an example of a pleiotropic variant exhibiting the predominant tune mechanism, we 
found that rs17758695 (PP = 0.99, 0.99, and 0.99) is associated with decreases in eosinophil, 
monocyte, and RBC count (Fig. 4e). This variant is located within a progenitor-specific 
region of AC in the intron of BCL2, an anti-apoptotic protein known to regulate 
hematopoietic differentiation48. This is consistent with the idea that regulating a general cell 
death protein such as BCL2 in a common multipotential progenitor would tune the 
production of multiple cell types, in contrast to the switch variants proximal to key 
regulators of hematopoietic differentiation. An additional tune variant is the missense variant 
rs12459419 (PP = 0.30, 0.28, and 0.11) in the CD33 gene, which is associated with 
decreases in eosinophil, monocyte, and platelet counts. CD33 is broadly expressed in 
hematopoietic progenitors and is a surface marker of myeloid differentiation49 
(Supplementary Fig. 12). In summary, our analyses support a prominent role for pleiotropy 
in hematopoietic differentiation, whereby individual variants can act in upstream progenitors 
to simultaneously tune or switch production and maintenance of multiple lineages.
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g-chromVAR, a novel method to measure fine-mapped GWAS enrichment amongst closely 
related tissues.
We next shifted our focus in the reciprocal direction – using fine-mapping to determine the 
exact stages of human hematopoiesis at which regulatory genetic variation underlying each 
blood cell trait is most likely acting. Although recent methods11,17 have been developed to 
calculate enrichment of genetic variation with genomic annotations, a method which 
accounts for both (i) the strength and specificity of the genomic annotation and (ii) the 
probability of variant causality, accounting for LD structure, is needed to resolve 
associations within the closely related, stepwise hierarchies that define hematopoiesis. To 
these ends, we developed a new approach called genetic-chromVAR (g-chromVAR), a 
generalization of the recently described chromVAR method,50 to measure the enrichment of 
regulatory variants in each cell state using fine-mapped variant PPs and quantitative 
measurements of regulatory activity (Fig. 5a; see Supplementary Note and Online Methods 
for details). We show that g-chromVAR is generally robust to variant PP thresholds and 
numbers of background peaks (Supplementary Fig. 13), captures true enrichments in a 
simulated setting (Supplementary Fig. 14), is robust to the choice of fine-mapping method 
(Supplementary Table 10), and can identify novel enrichments in large epigenomic datasets 
(Supplementary Table 11; see Supplementary Note for details).
In order to validate g-chromVAR in a realistic setting, we used it along with seven other 
methods to estimate the enrichment of each of the 16 blood cell traits within the accessible 
chromatin of 18 hematopoietic progenitor and terminal cell populations (Figs. 1a and 5c, 
Supplementary Figs. 15 and 16, Supplementary Table 4)34,35. To compare g-chromVAR’s 
performance to other state-of-the-art enrichment tools, we leveraged our knowledge of the 
hematopoietic system and devised a lineage specificity test (see Supplementary Note), which 
is a nonparametric rank-sum test that compares the relative ranking of lineage specific and 
non-lineage specific enrichments for each of the compared methodologies. We found that g-
chromVAR was the most specific of all tested methods, while still retaining sufficient power 
to identify 22 trait-cell type associations (Fig. 5d, and Supplementary Figs. 13a and16).
Having validated our approach, we investigated cell type enrichments for each of the 16 
traits. We found that the most lineage-restricted or terminal populations were typically most 
strongly enriched for a corresponding trait association (Fig. 5e–h). For example, RBC count 
was most strongly enriched in erythroid precursors (Fig. 5e), and lymphocyte count was 
most strongly enriched in CD4+ and CD8+ T cells (Fig. 5h). In several instances, we 
observed significant enrichments for traits in earlier progenitor cells within each lineage, 
including enrichment for platelet traits in CMPs and enrichment for monocyte traits in a 
specific subpopulation of GMPs (Supplementary Fig. 13a). We sought to investigate these 
progenitor enrichments further at the single cell level.
GWAS enrichment in single-cell chromatin accessibility data.
Although the strongest g-chromVAR enrichments for blood traits were in the most lineage 
restricted precursors, we reasoned that investigating progenitor populations that did have 
robust enrichment signals, such as CMPs and MEPs, could inform principles of the genetic 
regulation of terminal blood cell production51–54. To these ends, we scored 2,034 single 
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bone-marrow derived hematopoietic stem and progenitor cells34 for GWAS enrichment 
using g-chromVAR (Fig. 6a). Single-cell composite and bulk cell type enrichments were 
highly correlated (r = 0.84) (Fig. 6b), and enrichments along inferred pseudotime trajectories 
of cellular differentiation mirrored our observations from bulk data, albeit with finer 
granularity (Fig. 6c,d). These results suggest that g-chromVAR is able to recover known 
biology from sparse single cell (sc-)ATAC-seq profiles.
To explore potential heterogeneity within each of the 11 hematopoietic progenitor 
populations, we estimated the variation in regulatory genetic enrichments for each trait 
within populations. We found that classically defined CMP (n = 502 cells) and MEP (n = 
138 cells) populations exhibited significant heterogeneity in g-chromVAR enrichments for 
both erythroid and megakaryocyte traits (Fig. 6e). We thus hypothesized that the CMP 
population could be subdivided into megakaryocyte/erythrocyte-primed and monocyte-
primed subtypes, whereas the MEP population could be further subdivided into erythrocyte-
primed and megakaryocyte-primed subtypes. To test this hypothesis, we performed 
unsupervised clustering on chromatin accessibility profiles for the CMP and MEP 
populations (Supplementary Fig. 17) and found that the (GWAS-naïve) subpopulations were 
indeed differentially enriched for the specific GWAS traits. In agreement with these genetic 
enrichments, we observed differential chromatin accessibility of motifs for lineage-specific 
master TFs between the subpopulations that corresponded to the trait enrichments, such as 
increased chromatin accessibility of GATA1 motifs within the clusters enriched for erythroid 
traits (Fig. 6f,g and Supplementary Table 12). Additional studies are needed to determine 
whether these differences are due to distinct lineage-biased subpopulations or whether they 
reflect gradations along a common axis of differentiation. Regardless, our findings 
demonstrate that genetic variation acts heterogeneously within classically defined progenitor 
populations.
Discussion
Two outstanding challenges in the post-GWAS era are (i) the precise identification of causal 
variants within associated loci and (ii) determination of the exact mechanisms by which 
these variants result in the observed phenotypes. To address (i), we used robust genetic fine-
mapping to identify hundreds of putative causal variants for 16 blood cell traits, allowing for 
up to 5 causal variants in each locus. At PP > 0.10, we identified 240 fine-mapped coding 
variants as well as 647 regulatory variants in AC in at least one of 18 primary hematopoietic 
populations. Several compelling anecdotes, including a number of instances in which the 
activity of a single regulatory element is modulated by multiple functional variants, highlight 
the advantages of allowing for multiple causal variants when fine-mapping.
To address (ii), we compiled and derived functional annotations to nominate regulatory 
mechanisms and identify putative target genes. Overall, our comprehensive approach 
identified a high confidence regulatory mechanism for 145 variants and an experimentally 
supported target gene for 79% of variants in AC for distinct lineages. Our investigations into 
these fine-mapped pleiotropic variants revealed that ~90% of these variants act to tune total 
hematopoietic production, whereas the remaining ~10% favored production of one lineage at 
the expense of another (switch). To further improve causal cell type identification, we 
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developed a novel enrichment method (g-chromVAR) that can discriminate between closely 
related cell types and applied it to directly probe the regulatory dynamics of hematopoiesis 
within classically defined progenitors in bulk and at the single cell level. Our “top loci” 
method is complementary to enrichment methods that investigate polygenic signals, such as 
S-LDSC.
Overall, our integrated approach is designed to sequentially identify causal genetic variants, 
their molecular mechanisms, their target genes, and the cell types in which they act. We 
expect that better-powered fine-mapping studies, more numerous and higher quality bulk 
and single-cell epigenomic datasets, and improved computational tools will extend the 
inferences discussed herein. Altogether, our study represents a paradigm for the 
comprehensive mapping of variant to function, which can be applied broadly to gain insights 
into the specific functions of variants associated with a range of human traits and diseases.
URLs.
A UCSC Genome Browser visualization hub for all bulk ATAC data is available with this 
hub URL: https://s3.amazonaws.com/atachematopoesis/hub.txt. The web app to visualize 
putative causal variants and corresponding annotations is available at http://
molpath.shinyapps.io/ShinyHeme. Functional genomic annotations are available here: 
https://github.com/caleblareau/singlecell_bloodtraits/tree/master/data/annotations.
Online Methods
Genome-wide association studies.
Genome-wide association studies were carried out for 16 different blood cell indices in 
114,910–116,667 “white British” individuals from UK Biobank. Imputation was performed 
using the combined 1000 Genomes Phase 3-UK10K panel (http://biobank.ctsu.ox.ac.uk/
crystal/refer.cgi?id=157020). To account for population substructure in blood cell traits, we 
regressed each phenotype against the first 10 principal components of genetic ancestry, age, 
and sex. We then inverse normalized the residuals, which were used as the phenotype 
measurements for the genetic association tests. Specifically, we regressed each phenotype 
measurement against the probabilistic imputed allele dosage using a linear mixed model 
approach as implemented in BOLT-LMM v2.255. Genome-wide significance was defined as 
P < 5 × 10−8.
Linkage disequilibrium score regression.
We used LD score regression (LDSC) to compute the narrow-sense heritability estimates 
and genetic correlations of the 16 blood cell traits in the UKB. Reference LD scores were 
computed with a subset of unrelated European individuals from the UK10K cohort. To 
remove genetically related individuals, we first used PLINK to construct a filtered list of 
variants with MAF > 0.10 and no pair of variants with R2 > 0.10. These LD and MAF-
pruned variants were then used to calculate an identity-by-descent (IBD) matrix, and one 
individual in each pair of samples with proportion IBD (π) > 0.125 were removed to produce 
a final subset of 3,677 unrelated individuals to serve as the reference panel for LDSC. After 
applying the recommended variant filtering, z-scores for an average of 6,655,000 variants 
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per trait were used as input to LDSC. For heritability estimates for variants identified by 
fine-mapping or by linkage to the sentinel, we note that these estimates may be either over-
estimated or under-estimated from the reported values as previously noted56.
Fine-mapping.
Sentinel association regions were constructed as follows: first, all variants were ranked by 
decreasing χ2statistics. Next, we derived 3-Mb regions centered at the top variant; each 
region is ~3 cMs, so all relevant LD structure should be fully captured for nearly every 
region (Yu et al.57 reported that 95% of region recombination rates fall within 3 Mb). This 
process was repeated for each top association variant that did not overlap any 3-Mb regions 
created thus far until there were no genome-wide significant variants remaining in undefined 
regions. Within each region, we identified all imputed variants with MAF > 0.1% and 
imputation quality (INFO) > 0.6 and extracted z-scores from the summary statistics for each. 
We next derived dosage LD matrices for each region using LDstore15 on the genotype 
probability files (.bgen) used for the association studies. To be exact, we computed LD 
matrices from 120,086 individuals who had a phenotype for at least one of the 16 blood cell 
traits.
Fine-mapping was performed on genome-wide significant GWAS regions using FINEMAP 
v1.1 software with the z-score and LD matrices as input16. The output from FINEMAP is (i) 
a list of potential causal configurations together with their posterior probabilities and Bayes 
Factors, (ii) the posterior probability marginalized over the causal configurations that 
individual variants are causal, and (iii) the posterior probabilities that there are a specific 
number (between 1 and 5) of statistically independent associations in each region. Default 
FINEMAP settings were used and all variants with posterior probabilities > 0.1% were 
retained for downstream analyses. For the CCND3 and AK3 regions in which follow-up 
luciferase reporters were performed, we reran FINEMAP allowing for up to 10 causal 
variants, confirming ~4 independent effects in the CCND3 locus (60.6% posterior 
probability) but revealing ~8 independent effects for the AK3 locus (59.9% posterior 
probability).
To confirm select regions with multiple putative causal variants, we performed conditional 
analysis using BOLT-LMM by first conditioning on the variant with the lowest P-value in 
the region and then stepwise adding to the model the variant with the lowest conditional P-
value until no additional variant reached the genome-wide significance threshold of 5 × 10−8 
in the combined model.
Local annotation shifting.
We implemented a slightly modified version of GoShifter to calculate the enrichment 
between fine-mapped variants with PP > 0.01 for every trait and 5 different genomic 
annotations (see Supplementary Note for details). To obtain the annotation for hematopoietic 
AC, we used the consensus peak set for all blood cell types, performed row and column 
quantile normalization on the counts matrix, and kept only peaks that had a maximum count 
in the top 80% for at least one of the 18 cell types. The coding, intron, promoter, and 5’ 
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untranslated region annotations were obtained from the UCSC Genome Browser as 
previously processed (see URLs)12.
Variant classification and annotation.
To partition fine-mapped variants into bins of non-overlapping annotations (Figs. 1f,g and 
4b), we overlapped variant positions with genomic intervals and then classified each variant 
based on the following hierarchy: (i) coding; (ii) promoters; (iii) UTRs; (iv) hematopoietic 
chromatin accessible; (v) intronic; and (vi) intergenic. For example, for a variant falling in 
an AC region that is an annotated promoter, this variant was assigned to the “promoter” 
class. Variant effect predictor (VEP) was used to further annotate the functions of coding 
variants58.
To define pleiotropic variants and relative effect directions, we considered a subset of 7 of 
the 16 total traits that were defined “count” traits for distinct cell types: basophil, eosinophil, 
neutrophil, platelet, red blood cell, monocyte, and lymphoid count were the traits used for 
their respective lineages. Note that basophil, eosinophil, and neutrophil count were 
represented together as granulocytes for visualization purposes (Fig. 4b), but still considered 
as distinct cell types. “Tune” variants were defined as those that exhibited the same direction 
of effect for the minor allele across all lineages. Conversely, “switch” variants were 
designated when the minor allele had differing effect directions for two or more lineages.
Gene set enrichment analysis.
Gene set enrichments of fine-mapped coding variants with PP > 0.10 were calculated using 
Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA)59, 
using all protein-coding genes as the background model and requiring a minimum overlap of 
two genes and an FDR-adjusted P < 0.01 for each gene set. Only Gene Ontology (GO) 
biological processes were considered.
ATAC and scATAC sequencing and data preprocessing.
Chromatin accessibility profiles for a total of 18 populations, including 16 previously 
reported, were assayed using FastATAC, an optimized ATAC-seq protocol optimized for 
primary blood cells, as previously described35,60. Sequencing data for each of the 18 
populations was uniformly processed using a custom pipeline that includes sequencing 
adaptor removal, alignment using Bowtie261, and PCR duplicate removal with Picard 
RemoveDups command.
Accessible chromatin peaks were called from the 18 sorted populations of blood cells using 
MACS262. To derive a consensus set of loci for downstream analysis, individual peaks were 
resized to a uniform width of 500 bp, centered at the summit from the MACS2 call as 
previously described35. To derive a consensus peak set for the blood cell types, peaks were 
combined by removing any other peak overlapping with a peak with greater signal at the 
summit within a particular cell type. A total of 451,283 peaks representing a consensus set 
across these 18 sorted bulk populations were called. The average number of fragments in 
this consensus peak set ranged from 4.4 million (pDCs) to 37.1 million (CMPs) for a mean 
of 19.3 million reads in peaks per sorted cell type (Supplementary Table 4).
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FACS-sorted cells from 9 distinct cellular populations from CD34+ human bone marrow, 
which included cell types spanning the myeloid, erythroid, and lymphoid lineages, were 
additionally profiled as previously described34,60. Single-cells were sorted then assayed 
using scATAC-seq34,63 across a total of 30 independent single-cell experiments representing 
6 human donors, with each population assayed from two or more distinct donors. In total, 
our raw data set comprised 3,072 single-cell chromatin accessibility landscapes with 2,034 
cells passing stringent quality filtering. These cells yielding a median of 8,268 fragments per 
cell with 76% of those fragments mapping to peaks, resulting in a median of 6,442 
fragments in peaks per cell again using a consensus peak set that was inferred for these 
specific progenitor populations34.
To infer dynamic GWAS enrichments across hematopoietic differentiation, pseudotime 
orderings of single cells across three lineages (erythroid, lymphoid, and myeloid) were 
estimated using an adaptation of the Waterfall algorithm64 as previously described. In brief, 
this supervised approach fits a regression line through the relevant cluster centroids (k total = 
14) in principal component space. The pseudo-time values then represent the Euclidean 
distance along the interpolated lines. Lines are scaled such that the center of the HSC cluster 
is 0 in all trajectories. Further details and diagnostics of this approach are discussed in a 
previous work64.
To assess regulatory heterogeneity of single cells, we computed a chi-squared statistic for 
each trait/cell type’s z-scores to test whether the observed variance was greater than 
expected. Under the null, the variance of z-scores is 1 from the definition of our statistic (see 
g-chromVAR methods below), and we observed greater variation than expected only for 
traits within the CMP and MEP populations. Within CMP and MEP populations, we applied 
k-medoids clustering on the first 5 principal components within each sorted population from 
global chromatin accessibility profiles for each cell34. For both the CMPs and MEPs, the 
optimal cluster number was determined by maximum average silhouette width. Post-hoc 
analyses of heterogeneity within the partitioned clusters of the erythroid-enriched CMPs 
confirmed that megakaryocyte-erythroid enrichment was not distinct within CMPs.
Isolation of mDCs and pDCs.
Peripheral blood cells from healthy volunteers were enriched for cell surface markers using 
the strategy shown in Supplementary Figure 7. 55,000 cells from two healthy volunteers 
(two replicates total) were sorted into RPMI1640 medium supplemented with 10% FBS, 
washed with PBS and immediately transposed as previously above. Post-sort purities of > 
95% were confirmed by flow cytometry for all of the samples.
Target gene identification.
Raw sequencing reads from sorted populations were obtained from bulk RNA-seq 
experiments previously described34,35 and were aligned to the hg19 reference genome using 
STAR version 2.5.1b65 with default parameters. Per-gene transcript quantifications were 
summed over biological and technical replicates to provide a single transcript count per 
sorted cell type for 16 total populations matching the analogous bulk ATAC profiles (RNA 
for megakaryocytes and mDCs was absent). To determine empirical peak-gene associations, 
Ulirsch et al. Page 13
Nat Genet. Author manuscript; available in PMC 2019 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pearson correlation was computed for each peak within a 1-Mb window of the transcription 
start site per gene using the log counts per million value for each feature.
PCHi-C for 15 terminal hematopoietic datasets as well as for CD34+ hematopoietic stem 
and progenitor cells were processed as previously reported33,66. Specifically, variants in AC 
regions were only considered to physically interact with a gene’s promoter when the 
CHiCAGO score was > 5.
Transcription factor motif analysis.
Prediction of the effects of fine-mapped variants on transcription factor binding sites (TFBS) 
was performed using the motifbreakR package67 and a comprehensive collection of human 
TFBS models (HOCOMOCO22). For all fine-mapped variants with PP > 0.1%, we applied 
the “information content” scoring algorithm and used a P-value cutoff at 5 × 10–4 for a 
TFBS match; all other parameters were kept at default settings.
To identify recurrent motifs that were disrupted by fine-mapped variants or were spatially 
proximal to these motifs, we used the findOverlaps() function from the GenomicRanges 
package68. To identify variants near motifs (Supplementary Fig. 8d), we extended the range 
of the motif 20 bp in both directions. For either motif breaking variants or motif proximal 
variants, variant/motif pairs were filtered such that they intersected a relevant factor in 
hematopoietic tissue from 2,115 uniformly processed datasets in ChIP-Atlas. Relevant TFs 
were defined by “bagging” motifs based upon the similarity of their position weight matrices 
(Pearson r > 0.7). A match was determined when the exact name of the TF from the ChIP-
Atlas dataset exactly matched the name of the motif or any motif in the same “bag”. 
Conservation profiles for example motif disrupting variants were obtained are PhyloP 
estimates69.
To determine whether specific TFs were disrupted or proximal to variants more than 
expected by chance, we performed 100,000 permutations where we sampled the same 
number of unique variants with PP > 0.10 from across all variants in the 2,054 investigated 
regions. The expected number of TFs that were disrupted or proximal to variants was taken 
to be the mean across all permutations and significance was determined as one over the 
number of times that the number of overlaps was greater for PP > 0.10 than for the random 
sample.
Luciferase reporter analysis.
Firefly luciferase reporter constructs (pGL4.24) were generated by cloning the variant(s) of 
interest centered in 300–400 nucleotides (AK3 325 bp; CCND3 363 bp) of genomic context 
upstream of the minimal promoter using BglII and XhoI sites. The Firefly constructs (500 
ng) were co-transfected with a pRL-SV40 Renilla luciferase construct (50 ng) into 100,000 
K562 cells using Lipofectamine LTX (Invitrogen) according to manufacturer’s protocol. 
After 48 h, luciferase activity was measured by Dual-Glo Luciferase assay system 
(Promega) according to manufacturer’s protocol. For each sample, the ratio of Firefly to 
Renilla luminescence was measured and normalized to the empty pGL4.24 construct.
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A total of four haplotypes were constructed per locus to examine the effects of two fine-
mapped putative causal variants. For the CCND3 locus, we examined the effects of 
rs112233623 (ref: C, alt: T) and rs9349205 (ref: G, alt: A), which are 161 bp apart. For the 
AK3 locus, we examined rs409950 (ref: A; alt: C) and rs12005199 (ref: A, alt: G), which are 
separated by 123 bp. A total of nine (n = 9) experimental replicates per haplotype (four 
haplotypes per locus), including the empty pGL construct, were measured across two 
experimental batches.
To compute the additive and multiplicative effects of each variant, we used a generalized 
linear model of the following form for both of the AK3 and CCND3 loci separately:
Intensity   β0 + β1SNP1alt + β2SNP2alt + β3 SNP1alt ∗ SNP2alt + β4B
Here, the luciferase intensity is defined as the ratio of Firefly to Renilla luminescence 
normalized to the empty vector for each experimental replicate. The additive effects of the 
two SNPs were estimated using β1 and β2 whereas the multiplicative effect of both SNPs on 
the same haplotype was computed using an interaction term, β3. We encoded each variable 
such that the reference allele was a 0 whereas the alternate allele was a 1 for each 
experimental sample. Finally, we adjusted for variable infection efficiency between the 
experimental batches using a fixed effect variable B (B ∈ {0,1}). To increase power, point 
estimates and standard errors were realized directly from the linear model using the β 
coefficients from each reporter set rather than the mean of the specific haplotype.
g-chromVAR methodology.
The bias-corrected enrichment statistics for T traits and a set of S samples (chromatin cell 
type profiles) with P peaks computed by g-chromVAR is a generalization of the chromVAR 
method50. Intuitively, our implementation of g-chromVAR relaxes the requirement in 
chromVAR that trait-peak annotations be binary, allowing for uncertainty in annotations 
such as transcription factor binding or in our case, localization of GWAS variants (see 
Supplementary Note for details). Briefly, we use a matrix of variant posterior probabilities 
G, where gikis the sum of the posterior probabilities of the variants contained in the genomic 
coordinates of peak i for each trait k. Using the matrix of fragment counts in peaks X, where 
xij represents the number of fragments from peak i in sample j, a matrix multiplicationXT·G 
yields the total number of fragments weighted by the fine-mapped variant posterior 
probabilities for S samples (rows) and T traits (columns). To compute a raw weighted 
accessibility deviation, we compute the expected number of fragments per peak per sample 
in E, where eij is computed as the proportion of all fragments across all samples mapping to 
the specific peak multiplied by the total number of fragments in peaks for that sample:
ei, j =
∑ j xi, j
∑ j∑i xi, j
Σixi, j
Analogously, XT·E ields the expected number of fragments weighted by the fine-mapped 
variant posterior probabilities for S samples (rows) and T traits (columns). Using the G, X, 
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and E matrices, we then compute the raw weighted accessibility deviation matrix Y for each 
sample j and trait k (yj,k) as follows:
y j, k =
∑i = 1
P xi, jgi, k −∑i = 1
P ei, jgi, k
∑i = 1
P ei, jgi, k
To correct for technical confounders present in assays (differential PCR amplification or 
variable Tn5 tagmentation conditions), each peak is assigned a background set of peaks that 
are matched in mean nucleotide GC content and average fragment accessibility between the 
sums of the cell types. An inverse Cholesky transformation is applied to a P by 2 matrix 
containing these variables to generate two uncorrelated dimensions describing the per-peak 
confounding. The matrix B(b) encodes this background peak mapping where bi, j
b
 is 1 if peak 
i has peak j as its background peak in the b background set (b ∈ {1,2,…,50})and 0 
otherwise. The matrices B(b) ·X and B(b) ·E thus give an intermediate for the observed and 
expected counts also of dimension P by S. For each background set b, sample j, and trait k, 
the elements y j, k
b
 of the background weighted accessibility deviations matrix Y(b)are 
computed as follows:
y j, k
b =
∑i = 1
P B b ∙ X
i, kgi, k −∑i = 1
P B b ∙ E
i, kgi, k
∑i = 1
P B b ∙ E
i, kgi, k
After the background deviations are computed over the 50 sets, the bias-corrected matrix Z 
for sample j and trait k (zj,k) can be computed as follows:
z j, k =
y j, k − mean y j, k
b
sd y j, k
b
where the mean and variance of y j, k
b
 is taken over all values of b (b ∈ {1,2,…,50}). Sample-
trait P-values can then be computed from the one-tailed normal distribution of these z-scores 
using the pnorm function in R. Our implementation of g-chromVAR utilizes efficient matrix 
operations for each step and can compute pair-wise trait-cell type enrichments in ~1 minute 
on a standard laptop computer.
Other cell-type enrichment methods.
To estimate cell type enrichments for each trait using stratified LDSC (S-LDSC), we 
partitioned each trait’s heritability into the baseline model of 53 annotations, as well as each 
of the 18 hematopoietic ATAC-seq annotations (one at a time). Similarly, GREGOR70, 
GPA71, and fGWAS72 were run using the same 18 hematopoietic ATAC-seq annotations 
(one at a time) using default parameters for single trait and single annotation enrichments. P-
values for cell-type enrichment were required to meet a stringent Bonferroni threshold of 
0.00017 (corrected for 16 traits and 18 cell types).
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Reporting Summary.
Further information on research design is available in the Life Sciences Reporting 
Summary linked to this article.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1 |. Overview of hematopoiesis, UKB GWAS, and fine-mapping.
(a) Schematic of the human hematopoietic hierarchy showing the primary cell types 
analyzed in this work. Colors used in this schematic are consistent throughout all figures. 
Mono, monocyte; gran, granulocyte; ery, erythroid; mega, megakaryocyte; CD4, CD4+ T 
cell; CD8, CD8+ T cell; B, B cell; NK, natural killer cell; mDC, myeloid dendritic cell; 
pDC, plasmacytoid dendritic cell. The 16 blood traits that were genetically fine-mapped are 
shown below the hierarchy. (b) Schematic of UKB GWAS and fine-mapping approach. 
Briefly, blood traits from ~115K individuals were fine-mapped allowing for multiple causal 
variants and using imputed genotype dosages as reference LD. (c) Number of fine-mapped 
regions for each trait with the highest posterior probability for a variant being causal 
indicated. (d) Breakdown of the number of causal variants (min = 1, max = 5) for all regions 
in each trait. (e) Empirical distribution of the minor allele frequency of variants in each 
posterior bin. (f) Proportion of fine-mapped variants within intronic, promoter, coding, UTR, 
and intergenic regions. (g) Local-shifting enrichments of fine-mapped variants across all 
traits for varying posterior probability bins.
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Figure 2 |. Mechanisms of core gene regulation in blood production.
(a,b) Heatmaps depicting red blood cell trait-associated variants (PP > 0.10) across the 
erythroid lineage (a) and lymphocyte count-associated variants (PP > 0.10) across the 
lymphoid lineage (b), clustered by chromatin accessibility. Each row marks a fine-mapped 
variant, each column denotes a cell type within the relevant lineage, and color denotes 
relative chromatin accessibility along the lineage at each variant (blue, least accessible 
chromatin; red, most accessible chromatin). Putative target genes (predicted by ATAC-RNA 
correlation and/or PCHi-C) and disrupted TFs (predicted by ChIP-seq occupancy and motif 
disruption) are indicated to the right. (c) Transcription factor motifs disrupted in lineage-
specific hematopoietic traits. Each row represents a set of traits where variants disrupt 
specified TF motifs and are occupied by that TF in hematopoietic cells. The unique margin 
sums across each lineage are shown in the bar plot for each TF. The expected number of 
variants with ChIP + motif disruption across all PPs is estimated using 100,000 permutations 
and is shown as a single point. (d) Examples of molecular mechanisms from the analysis in 
c reveals putative causal variants that disrupt cis-binding of hematopoietic TFs known to be 
involved in regulating hematopoiesis for various blood cell traits: rs10758656 and 
rs66480687 are associated with red blood cell traits; rs75522380 and rs74340846 are 
associated with platelet traits; rs4970966 is associated with monocyte count; and 
rs79716587 is associated with lymphocyte count. Black color represents accessibility 
throughout hematopoiesis, whereas other stacked colors represent accessibility for the cell 
types shown in Figure 3d. (e) Examples of putative target genes from the analysis in a and b: 
rs11642657 and rs12151289 are associated with monocyte count; rs73660574 is associated 
with red blood cell traits; rs553535973 is associated with lymphocyte count; and 
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rs114694170 is associated with platelet traits. Colors for accessible chromatin are the same 
as in d.
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Figure 3 |. Characterization and validation of CCND3 and AK3 regions with multiple causal 
variants.
(a,b) Regional association plots (n = 116,667 individuals; BOLT-LMM P-values) for RBC 
count in the CCND3 locus from the initial GWAS (a) and after conditioning on the sentinel 
variant rs9349205 (b). (c,d) Fine-mapping identifies two putative causal variants 
(rs9349205, PP = 0.94; rs112233623, PP = 0.99) located 161 bp apart (c), both of which lie 
within the same erythroid-specific accessible chromatin (AC) (d). (e) Luciferase reporter 
assays for four haplotypes (left) corroborate independent additive effects of rs9349205 (red; 
P = 1.78 × 10−3) and rs112233623 (blue; P = 2.86 × 10−6) on RBC count (right). (f,g) 
Regional association plots (n = 116,666 individuals, BOLT-LMM P-values) for platelet 
count in the AK3 locus from the initial GWAS (f) and after conditioning on sentinel variant 
rs12005199 (g). (h,i) Fine-mapping identifies two putative causal variants (rs12005199, PP 
= 0.99; rs409950, PP = 0.99) 123 bp apart (h), both located within a strong megakaryocyte 
AC region (i). (j) Luciferase reporter assays (n = 9 biological replicates) for four haplotypes 
(left) corroborate independent additive effects of rs12005199 (red; two-sided Wald test P = 
5.19 × 10−4) and rs409950 (blue; two-sided Wald test P = 3.57 × 10−5) on platelet count 
(right). Mean and standard error are indicated for both phenotype and regulatory activity.
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Figure 4 |. Dissecting mechanisms of pleiotropic variants across multiple blood cell lineages.
(a) Schematic that illustrates fine-mapped variants acting in multi-potential or heterogeneous 
progenitors on distinct hematopoietic lineages, either by tuning lineages in the same 
direction or switching the regulation in opposite directions. (b) A heatmap depicting 172 
fine-mapped variants (PP > 0.10) with pleiotropic effects on cell counts in two or more 
hematopoietic lineages (eosinophil, neutrophil, basophil, lymphocyte, monocyte, platelet, 
RBC). Effects on eosinophil, neutrophil, and basophil counts are visualized together as a 
singular granulocyte lineage. Genomic annotations are indicated below each variant. (c) 
Pleiotropic variant rs78744187, located downstream of CEBPA, has high chromatin 
accessibility in CMP and MEP progenitors (top) and demonstrates a switch mechanism by 
downregulating basophil count while upregulating RBC count (bottom). (d) rs218265, 
located upstream of stem cell factor KIT, has high chromatin accessibility in several early 
progenitors (HSC, MPP, CMP, MEP) and demonstrates a switch mechanism by upregulating 
neutrophil and WBC count while downregulating RBC count. (e) rs17758695, located 
within an intron of anti-apoptotic factor BCL2, has high chromatin accessibility in several 
early progenitors (HSC, MPP, CMP, MEP) and exhibits a tuning mechanism, simultaneously 
downregulating eosinophil, monocyte, and RBC counts.
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Figure 5 |. Overview of g-chromVAR and application to hematopoietic cell types.
(a) Schematic showing inputs for continuous epigenomic data for each cell type and a matrix 
of fine-mapped variant posterior probabilities for GWAS traits. (b-d) Results from the 
application of g-chromVAR and three similar methods to 16 blood cell traits for 18 
hematopoietic cell types. (b) Quantile-quantile representation of the P-values from each 
method. (c) Overlap between methods for Bonferroni-corrected trait enrichments. (d) 
Lineage enrichment of all trait-pairs (n = 288 pairs) for each method. A two-tailed Mann-
Whitney rank-sum test was used to evaluate the relative enrichment of lineage-specific trait-
cell type pairs (true positives). (e-h) Enrichments for four representative traits using g-
chromVAR: mean corpuscular volume (e); mean platelet volume (f); monocyte count (g); 
lymphocyte count (h).
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Figure 6 |. Application of g-chromVAR to single-cell chromatin accessibility data.
(a) 2,034 hematopoietic single cells projected onto a three-dimensional principal 
components embedding. Single cells colored by g-chromVAR enrichment scores for mean 
reticulocyte volume reveal specific regulatory enrichment in the MEP population. (b) 
Validation of g-chromVAR enrichments using synthetic bulk populations from sums of 
single cells (n = 2,034 cells). Aggregated single-cell g-chromVAR z-scores across all trait-
cell type pairs (individual points) strongly correlate (Pearson r = 0.84) with bulk population 
z-scores. (c) Inferred pseudotime trajectories of three hematopoietic lineages from scATAC-
seq data. (d) Pseudotime trends (mean and 95% CIs) of g-chromVAR scores for platelet 
count across all single cells (n = 2,034 cells) corroborates regulatory dynamics of 
megakaryocyte/erythroid differentiation. (e) Rank order plot highlighting the trait-cell type 
pairs with the greatest variance over that of a χ2 distribution. (f) K-medoids partitioning of 
ATAC-seq counts in CMP cells (n = 502 cells) reveals two subpopulations: one that is 
enriched for monocyte genetic variants and one that is enriched for megakaryocyte/erythroid 
variants (RBC count, FDR = 1.28 × 10−4; MPV, FDR = 2.36 × 10−4; platelet count, FDR = 
1.40 × 10−5; monocyte count, FDR = 2.21 × 10−2). ChromVAR scores for master 
transcription factors (TFs) of each blood cell type support biological hypotheses for genetic 
enrichments (GATA1, FDR = 1.76 × 10−82; KLF1, FDR = 4.33 × 10−3; CEBPA, FDR = 2.58 
× 10−16; IRF8, FDR = 4.65 × 10−15). Two-tailed t-tests were used for each comparison; 
boxplots represent median and interquartile range. (g) Similar k-medoids partitioning of 
MEP cells (n = 138 cells) reveals two subpopulations with differential enrichments for 
megakaryocyte or erythroid associated genetic variants (RBC count, FDR = 0.155; HCT, 
FDR = 3.98 × 10−2; platelet count, FDR = 7.65 × 10−2), along with consistent differences in 
chromVAR TF-deviation scores for master TFs of each blood cell type (GATA1, FDR = 2.18 
× 10−4; KLF1, FDR = 4.02 × 10−6; MEF2C, FDR = 2.52 × 10−3).
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